[go: up one dir, main page]

WO2000066107A3 - Antimalarian agents for the treatment of asthma - Google Patents

Antimalarian agents for the treatment of asthma Download PDF

Info

Publication number
WO2000066107A3
WO2000066107A3 PCT/US2000/011658 US0011658W WO0066107A3 WO 2000066107 A3 WO2000066107 A3 WO 2000066107A3 US 0011658 W US0011658 W US 0011658W WO 0066107 A3 WO0066107 A3 WO 0066107A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
antimalarian
agents
treatment
treated
Prior art date
Application number
PCT/US2000/011658
Other languages
French (fr)
Other versions
WO2000066107A2 (en
Inventor
Lauren B Charous
Original Assignee
Apt Pharmaceuticals L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apt Pharmaceuticals L L C filed Critical Apt Pharmaceuticals L L C
Priority to CA2372443A priority Critical patent/CA2372443C/en
Priority to JP2000614992A priority patent/JP2002543122A/en
Priority to EP00928620A priority patent/EP1175216A2/en
Publication of WO2000066107A2 publication Critical patent/WO2000066107A2/en
Publication of WO2000066107A3 publication Critical patent/WO2000066107A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A diversity of inflammatory diseases can be treated via local delivery to the patient of a composition containing a therapeutically effective amount of an anti-malarial agent. In a preferred embodiment of the method of the invention, a pulmonary inflammatory condition, such as asthma, is treated by inhalation of an aerosolized anti-malarial agent, such as hydroxychloroquine.
PCT/US2000/011658 1999-04-30 2000-05-01 Antimalarian agents for the treatment of asthma WO2000066107A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2372443A CA2372443C (en) 1999-04-30 2000-05-01 Local administration of anti-malarial agents for the treatment of inflammatory diseases
JP2000614992A JP2002543122A (en) 1999-04-30 2000-05-01 New uses for antimalarial therapeutics
EP00928620A EP1175216A2 (en) 1999-04-30 2000-05-01 Antimalarian agents for the treatment of asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13200899P 1999-04-30 1999-04-30
US60/132,008 1999-04-30

Publications (2)

Publication Number Publication Date
WO2000066107A2 WO2000066107A2 (en) 2000-11-09
WO2000066107A3 true WO2000066107A3 (en) 2001-05-03

Family

ID=22452011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011658 WO2000066107A2 (en) 1999-04-30 2000-05-01 Antimalarian agents for the treatment of asthma

Country Status (5)

Country Link
US (2) US6572858B1 (en)
EP (1) EP1175216A2 (en)
JP (1) JP2002543122A (en)
CA (1) CA2372443C (en)
WO (1) WO2000066107A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
IL161821A0 (en) * 2001-11-09 2005-11-20 Lauren Charous Pharmaceutical compositions containing an aminoquinoline or a hydroxyquinoline derivative
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2005069731A2 (en) * 2004-01-22 2005-08-04 M.D.Z. Investments Ltd. Method for treating oral aphthous stomatitis and oral mucositis
US20070004680A1 (en) * 2004-03-30 2007-01-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP1877055A4 (en) * 2005-05-06 2008-10-01 Apath Llc 4-aminoquinoline compounds for treating virus-related conditions
RU2008135762A (en) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) METHODS AND COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
US20110092557A1 (en) * 2008-06-25 2011-04-21 Influmedix Inc. Neuraminidase Inhibitors And Compositions And Methods Related Thereto
EP2547335A4 (en) * 2010-03-15 2014-04-16 Univ Virginia Commonwealth AEROSOLIC DAPSONE AS THERAPY AGAINST INFLAMMATION OF THE RESPIRATORY SYSTEM AND ANOMALY OF MUCOCILIARY TRANSPORT
EP2603213A4 (en) * 2010-08-09 2014-02-19 Univ Maryland METHODS OF TREATING OBSTRUCTIVE PULMONARY DISORDERS USING BIRTHY SAPIC SUBSTANCES
CA2968345A1 (en) * 2014-11-18 2016-05-26 University Of South Florida Compositions and methods for treating endometriosis
MX394605B (en) 2015-06-30 2025-03-24 Eiger Group Int Inc USE OF CHLOROQUINE AND CLEMIZOL COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND CANCEROUS CONDITIONS.
EP3356530A4 (en) * 2015-09-30 2019-04-10 Celgene Alpine Investment Company II, LLC TLR MODULATORS AND ASSOCIATED METHODS OF USE
WO2018146171A1 (en) * 2017-02-09 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating mast cell activation diseases
WO2021191496A1 (en) * 2020-03-25 2021-09-30 Therapeutica Borealis Oy Medicine for covid-19 and treatment
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
JP2023544685A (en) 2020-09-14 2023-10-25 イスタンブル ウニヴェルシテシ レクトールルグ Use of active substances with antiviral, antimalarial and/or mucolytic properties in the treatment of viral lung diseases, including COVID-19, using soft mist inhalers or vibrating mesh nebulizers via the inhalation route
US20230355898A1 (en) * 2020-09-22 2023-11-09 Micronization Technologies And Therapeutics Group Llc Nebulizer and nebulized anti-virals
CN114452289B (en) * 2020-12-31 2023-06-09 兰州大学 Application of quinoline derivatives in preparation of medicines for preventing and/or treating gastrointestinal diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6298E (en) * 1905-04-14 1906-10-13 Friedrich Wellauer Removable toothbrush
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
WO1998017231A2 (en) 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US20020091139A1 (en) 1997-10-17 2002-07-11 Damon Todd Holdings, L.L.C. Treatment and delivery of hydroxychloroquine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARNES P J: "ASTHMA THERAPY WITH AEROSOLS: CLINICAL RELEVANCE FOR THE NEXT DECADE", JOURNAL OF AEROSOL MEDICINE,US,MARY ANN LIEBERT, INC., NEW YORK, vol. 9, no. 1, 1996, pages 131 - 141, XP000911157, ISSN: 0894-2684 *
CHAROUS B L ET AL: "Double-blind trial of hydroxychloroquine (HCQ) as anti-allergic anti-asthmatic therapy.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1 PART 2, 1997, Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society;San Francisco, California, USA; February 21-26, 1, pages S268, XP000974817, ISSN: 0091-6749 *
CHAROUS B L: "OPEN STUDY OF HYDROXYCHLOROQUINE IN THE TREATMENT OF SEVERE SYMPTOMATIC OR CORTICOSTEROID-DEPENDENT ASTHMA", ANNALS OF ALLERGY, vol. 65, no. 1, 1990, pages 53 - 58, XP000974393, ISSN: 0003-4738 *
CHAROUS B LAUREN ET AL: "Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 102, no. 2, August 1998 (1998-08-01), pages 198 - 203, XP000972584, ISSN: 0091-6749 *
JAMES E F REYNOLDS: "Martindale The Extra Pharmacopoeia", ROYAL PHARMACEUTICAL SOCIETY, LONDON, XP002156291 *
ORNSTEIN MATTHEW H ET AL: "The anti-inflammatory and antiviral effects of hydroxychloroquine (HCQ) in 2 patients with AIDS and active inflammatory arthritis.", ARTHRITIS & RHEUMATISM, vol. 38, no. 9 SUPPL., 1995, 59th National Scientific Meeting of the American College of Rheumatology and the 30th National Scientific Meeting of the Association of Rheumatology Health Professionals;San Francisco, California, USA, pages S198, XP000974815, ISSN: 0004-3591 *

Also Published As

Publication number Publication date
US7183112B2 (en) 2007-02-27
US20030224008A1 (en) 2003-12-04
JP2002543122A (en) 2002-12-17
US6572858B1 (en) 2003-06-03
EP1175216A2 (en) 2002-01-30
WO2000066107A2 (en) 2000-11-09
CA2372443A1 (en) 2000-11-09
CA2372443C (en) 2010-07-13

Similar Documents

Publication Publication Date Title
WO2000066107A3 (en) Antimalarian agents for the treatment of asthma
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
PL396553A1 (en) Using a factor for the preparation of a medicament for the treatment of glaucoma
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
BR0211450A (en) Therapeutic method
WO2004005286A3 (en) Viral inhibitors
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
CA2155933A1 (en) Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2002096423A3 (en) Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
WO2000045834A3 (en) Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AP2003002909A0 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2003039464A3 (en) Antimuscarinic aerosol
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
NO20054767L (en) Compositions comprising apomorphine for lung inhalation
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
WO2001015672A3 (en) Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
WO2003024996A3 (en) Antibacterial macrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2372443

Country of ref document: CA

Ref country code: CA

Ref document number: 2372443

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 614992

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000928620

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928620

Country of ref document: EP